Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Daily

Download Data

Milestone Pharmaceuticals Inc Market Capitalization on June 03, 2024: USD 80.42 M

Milestone Pharmaceuticals Inc Market Capitalization is USD 80.42 M on June 03, 2024, a -37.72% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Milestone Pharmaceuticals Inc 52-week high Market Capitalization is USD 133.82 M on June 08, 2023, which is 66.39% above the current Market Capitalization.
Milestone Pharmaceuticals Inc 52-week low Market Capitalization is USD 75.50 K on March 14, 2024, which is -99.91% below the current Market Capitalization.
Milestone Pharmaceuticals Inc average Market Capitalization for the last 52 weeks is USD 87.75 M.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends